BETA
Your AI-Trained Oncology Knowledge Connection!
Investigational Agent Improves PFS Vs Everolimus in Grade 1/2 GI NETs
Phase 3 data show that ITM-11 produced favorable safety results among patients with gastroenteropancreatic neuroendocrine tumors.
Belantamab Mafodotin Shows Real-World Efficacy in Pretreated R/R Myeloma
Having extramedullary disease correlated with worse PFS and OS among patients who received belantamab mafodotin for relapsed/refractory multiple myeloma.
Fluorescent-Based Imaging with AI Can Improve Surgery in Breast and Ovarian Cancer
The FIBI technology, created by Farzad Fereidouni, PhD, when combined with AI eliminates the need for frozen sections and other labor-intensive oncology surgery practices.
Inavolisib Combo Meets OS End Point in PIK3CA+ Metastatic Breast Cancer
The phase 3 INAVO120 trial reported statistically significant OS results in patients with PIK3CA-mutant, locally advanced or metastatic breast cancer.
T-DM1 Shows Promise in HER2+ Biliary Tract Cancer
A phase 2 trial found T-DM1 to be a tolerable treatment option for patients with HER2-positive biliary tract adenocarcinoma.
Encorafenib Combo Shows Universal Activity in CRC Prognostic Groups
Additional progression-free survival data from the phase 3 BREAKWATER trial will be presented at future meetings.
Data Monitoring Committee OKs INVINCIBLE-3 Sarcoma Trial Continuation
The phase 3 INVINCIBLE-3 trial is evaluating INT230-6 vs standard of care in locally recurrent, inoperable, or metastatic soft tissue sarcoma.
T-DXd Benefit May Extend to Earlier Settings and HER2-Low Breast Cancers
Regardless of disease burden or disease progression speed on front-line therapy, trastuzumab deruxtecan appears effective in HER2-low breast cancer.
CD19-directed CAR T therapy for T-cell/histiocyte-rich large B-cell lymphoma
Researchers from the University of Wisconsin, Cornell, and a consortium of other institutions conducted a retrospective analysis on CD19-directed CAR T-cell therapy for R/R T-cell/histiocyte-rich LBCL.
Inflammation-induced epigenetic imprinting regulates intestinal stem cells
Researchers from Bambino Gesù Children’s Hospital and Sapienza University in Rome, Italy examined the recovery and function of MAIT cells in pediatric and young adult patients following allo-HSCT.
Enhanced Postoperative Recovery May Improve Outcomes in Elderly NSCLC
Postoperative pulmonary complications were reduced with enhanced recovery after surgery vs control in elderly patients with non–small cell lung cancer.
FDA Approves T-DXd in HER2-Low/Ultralow Breast Cancer
Results from the DESTINY-Breast06 trial led to the approval of T-DXd for patients with unresectable or metastatic HER2-low or HER2-ultralow breast cancer.
Belzutifan Receives Priority Review in Pheochromocytoma/Paraganglioma
Data from the phase 2 LITESPARK-015 trial support the sNDA for belzutifan in patients with pheochromocytoma or paraganglioma.
Neoadjuvant Botensilimab Combo Elicits High MPR Rates in MSS/MSI-H CRC
The major pathologic response rate improved with extended time to surgery using botensilimab plus balstilimab in resectable colorectal cancer.
Positive Responses Demonstrated by Adagrasib and Cetuximab in KRAS G12C-Mutant mCRC
At a longer follow-up, adagrasib with cetuximab maintained meaningful efficacy and elicited an ORR of 34%, results from the phase 1/2 KRYSTAL-1 showed.
Fast Track Designation Given to Novel PET Imaging Agent in Prostate Cancer
The imaging agent led to changes in intended treatment plans for 48% of patients with prostate cancer and biochemical recurrence after definitive therapy.
Fruquintinib Combo Shows Activity in Pretreated Metastatic CRC
Phase 2 data may support fruquintinib plus TAS-102 as an alternative third-line treatment in patients with metastatic colorectal cancer.
Pembrolizumab Combo Does Not Meet OS End Point in Advanced Gastric Cancer
Pembrolizumab plus lenvatinib showed a safety profile consistent with previous reports evaluating the combination.
Ramucirumab/Somatostatin Displays Prolonged Survival in Advanced NET
A phase 2 trial revealed survival with ramucirumab plus somatostatin was consistent with other VEGF pathways in treating advanced neuroendocrine tumors.
Palliative Care Consultations Correlate With Improved QOL in Esophageal Cancer
Patients with esophageal cancer who received palliative care consultations during end-of-life treatment experienced a decreased financial burden compared with patients who did not.
Conducting Early Phase Trials of Promising Treatments in Neuro-Oncology
Shwetal Mehta, PhD, emphasizes her institution’s patient-focused and scientifically rigorous philosophy when developing new therapies in brain cancer.
Long-term Aspirin Use Decreased PIK3CA-Mutated Colorectal Cancer Recurrence
The ALASCCA trial found that the risk of disease recurrence was reduced by 51% for patients with PIK3CA-mutated colorectal cancer who took aspirin for 3 years.
Balstilimab Plus Botensilimab Enhances Response in MSS mCRC without Liver Mets
A phase 2 study evaluated the efficacy of balstilimab and botensilimab in patients with MSS metastatic mCRC without liver metastases.
Improved Responses in Colorectal Cancer With Encorafenib/Cetuximab Plus Chemo
The BREAKWATER trial found that encorafenib and cetuximab with mFOLFOX6 chemotherapy generated an ORR of 60.9% in BRAF V600E–mutated metastatic colorectal cancer.
ctDNA Shows High Recurrence Detection Sensitivity in Stage II/III CRC
Post-operative ctDNA testing led to a change in adjuvant management in 1 of 6 patients with stage II/III colorectal cancer treated in the BESPOKE trial.
Nivolumab/Ipilimumab Extends PFS in MSI-H/dMMR Metastatic Colorectal Cancer
Updated results support nivolumab/ipilimumab as a standard of care in patients with MSI-H or dMMR metastatic colorectal cancer.
Palliative Care May Improve EOL Comfort in Early-Onset Colorectal Cancer
The results of a real-world study support palliative care integration in patients with advanced early-onset colorectal cancer.
Watch-and-Wait Strategy Shows Safety in Rectal Cancer Responder Population
No differences in oncologic outcomes occurred between mandatory TME or selective WW strategy in rectal cancer responders to neoadjuvant therapy.
Real-World Data Show Poor Outcomes in BRAF V600E-Mutant Metastatic CRC
Synchronous metastatic status does not appear to affect survival among patients with resected BRAF V600E-mutated metastatic colorectal cancer.
Neoadjuvant Pembrolizumab Enhances Response in dMMR Colon Cancer
A pCR rate of 44% was observed when neoadjuvant pembrolizumab was given to patients with dMMR colon cancer.
